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Fibroblasts derived from the progeroid Werner syndrome (WS) show reduced replicative lifespan and a “stressed”
morphology, both phenotypes being alleviated by using the p38 MAP kinase inhibitor SB203580. Because p38 is a
major hub for the control of stress-signalling pathways we were interested in examining the possible role for
downstream kinases in order to refine our understanding of the role of p38 signalling in regulation of WS cell growth.
To this end we treated WS and normal fibroblasts with MK2 inhibitors to determine whether MK2 inhibition would
affect either the growth or morphology of WS cells. The first inhibitor, 7,8-dihydroxy-2,4-diamino-3-
cyanobenzopyranopyridine (inhibitor 2), resulted in inhibition of WS cell growth and had no effect on morphology,
effects that occurred below the level needed to inhibit MK2 and thus suggestive of inhibitor toxicity. The second
inhibitor, 2-(2-quinolin-3-ylpyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo-[3,2-c]pyridin-4-one (CMPD16), resulted in a
significant extension of WS fibroblast replicative capacity compared to normal cells. In addition, CMPD16 reverted the
WS cellular morphology to that seen in normal dermal fibroblasts. These data suggest that MK2 activity plays a
substantial role in proliferation control in WS cells. CMPD16 was not as effective in cellular lifespan extension as
SB203580, however, suggesting that, although MK2 is a downstream kinase involved in cell cycle arrest, other p38
targets may play a role. Alternatively, as CMPD16 is toxic to cell growth at levels just above those that extend lifespan,
it is possible that the therapeutic window is too small. However, as CMPD16 does show significant effects in WS
fibroblasts, this acts as proof-of-principle for the efforts to design and synthesise improved MK2 inhibitors. As MK2 is
involved in inflammatory processes and inflammation plays a major role in WS phenotypes, these data suggest MK2 as
a potential therapeutic target for the treatment of Werner syndrome.
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Werner syndrome (WS) is a genetic disorder where indi-
viduals show premature onset of many clinical features
of old age and is used as a model to investigate normal
ageing processes [1]. The molecular mechanism of WS
is related to accelerated cell ageing. Normal human cells
divide a limited number of times before entering replica-
tive senescence [2]. This is postulated to contribute to
normal human ageing [1] and fibroblasts from WS
patients have a much-reduced replicative capacity [3].
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reproduction in any medium, provided the ora stress response, and the stress-induced p38 MAP kin-
ase pathway is activated in young WS cells [3]. Treat-
ment with the p38 inhibitor SB203580 increased the
growth rate and the cellular life span of primary WS
fibroblasts, and rescued their senescent-like morphology
[3]. Essentially, SB203580 reverted the phenotypic char-
acteristics of WS fibroblasts, implicating a role for both
p38 and stress signalling in WS. These data suggested a
possible therapeutic role for p38 inhibitors in WS [4]. How-
ever, it has been shown that long-term use of p38 inhibitors
in both humans and mice has toxic effects and low thera-
peutic efficacy [5]. The reasons for this are unknown but
may relate to the complexities of the pathways regulated by
p38, which is at the hub of the stress-induced response and
regulates many downstream kinases and cellular processesl Ltd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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downstream of p38 may be advantageous due to the more
limited pathways affected. MAPKAPK2 (MK2) is one par-
ticularly attractive target [7] as it is known to regulate the
cell cycle [8], is involved in regulating cellular morphology
[9], and plays a role in inflammatory processes [10] that areFigure 1 Effects of MK2 inhibitors of the growth and morphology of
fibre phenotype of primary AG05229 cells grown in the presence of 5.0 μM
(c) Titration inhibition of MK2 profile by MK2.III as measured by HSP27 pho
AG04552 cells in the presence of MK2.III and SB203580 in population doub
increase in replicative capacity of WS fibroblasts compared to NDFs for the
average of two strains for both WS (AG05229 and AG03141) and NDFs (AG
reproduciblity. The lifespan is calculated by taking into account the PDs alr
repository, e.g., for AG05229 the lifespan for 5.0 μM MK2.III treatment is (26
SB203580 or MK2.III on the cellular morphology and F-actin stress fibre phe
same magnification.prevalent in WS [4]. In addition, the observation that mice
null for MK2 are viable, whereas mice null for p38 are le-
thal, suggests that therapeutic inhibition of MK2 may prove
less problematical than p38 inhibition [10].
Previous work using MK2 inhibitors in WS cells was
inconclusive because the inhibitors resulted in cessationWS fibroblasts. (a) Structures of the MK2 inhibitors. (b) F-actin stress
inhibitor 2 (a similar phenotype is seen at 2.5 μM). Bar = 100 μm.
sphorylation ELISA. (d, e) Growth of primary WS AG05229 and NDF
lings (PDs) versus days. (f) Histogram illustrating the percentage
various treatments with DMSO = 100% lifespan. This data is an
04552 and AG13152) as illustrated by the error bars thus showing
eady attained by the cells prior to arrival from the Coriell cell
.5 PD – 7 PD)/(20.5 PD – 7 PD) = 1.444 = 144.4%. (g) Effects of
notype of WS fibroblasts and NDFs. Bar = 100 μm; all panels
Table 1 Statistical tests
Treatment NDFs a WS a NDFs / WS b
MK2.III (5μM) p > 0.37 p < 0.05 p < 0.029
SB203580 (2.5μM) p < 0.05 p < 0.036 p < 0.014
a Probability that inhibitor treatment results in no significant extension of
replicative capacity for NDFs or WS fibroblasts compared to DMSO-treated
cells (paired t-test).
b Probability that the extension of replicative capacity seen for WS cells is not
greater than that seen for NDFs for same treatment (unpaired 2-tailed t-test).
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ability of the inhibitors to inhibit MK2 [11], suggesting
off-target issues (or cellular toxicity) that are a known
problem with MK2 inhibitors [7]. In addition, the WS cells
used previously were telomerase-immortalised rather than
primary cells. Although these telomerase-immortalised
cells share many of the aged features of primary WS cells
[12], they do show different behaviours in certain situa-
tions, as exemplified by the differential effects seen with
JNK1/2 inhibitors in these cell types [13].
In this current study, we grew primary WS AG05229 der-
mal fibroblasts to senescence in the continuous presence of
the MK2 inhibitor 7,8-dihydroxy-2,4-diamino-3-cyanoben-
zopyranopyridine (inhibitor 2 from [11]; see Figure 1a) at
2.5 μM and 5.0 μM (see Additional file 1 for materials and
methods). Previously use of this inhibitor at 2.5 μM had
no effect on the growth of telomerised WS cells whereas
10 μM was completely inhibitory [11]. Similarly, in this
work we found that inhibitor 2 at 2.5 μM had little effect
on the replicative capacity of primary WS cells (21 popula-
tion doublings (PDs) compared to 20.5 PDs for the DMSO
control), whereas 5.0 μM was inhibitory, albeit not com-
pletely (resulting in a replicative capacity of 16.1 PDs). In
addition inhibitor 2 had no effects on the aged morph-
ology of the cells, which retained extensive F-actin stress
fibres (Figure 1b; compare to Figure 1g middle left panel).
The data with inhibitor 2 suggest that either MK2 inhib-
ition reduces cellular growth, which is inconsistent with
the observation that MK2 can promote cell cycle arrest
[8], or that inhibitor 2 is having an off-target or toxic ef-
fect. Thus, in order to study the role of MK2 in signalling
processes in WS cells, novel MK2 inhibitors with better
target specificity are required and the pharmaceutical in-
dustry is making a major effort in this direction [7].
Recently, the inhibitor 2-(2-quinolin-3-ylpyridin-4-yl)-
1,5,6,7-tetrahydro-4H-pyrrolo-[3,2-c ]pyridin-4-one
(CMPD16 of [14]; see Figure 1a) became commercially
available (designated as MK2.III). This inhibitor is prom-
ising due to its potency and good target specificity [14].
MK2.III prevented anisomycin induced HSP27 phos-
phorylation in human fibroblasts with an IC50 below 2.5
μM, which is in good agreement with the published IC50
seen in U937 cells [14], and showed maximal inhibition
at 10 μM (Figure 1c). We thus grew two primary normal
dermal fibroblast (NDF) and WS fibroblast strains in the
presence of MK2.III at various concentrations (2.5, 4.0,
5.0 and 10 μM) and compared the replicative capacity
with untreated cells and with cells grown in the presence
of 2.5 μM SB203580. The primary normal fibroblast
strains chosen were from elderly individuals and have
replicative capacities in the same range as seen in the
WS fibroblasts [15]. MK2.III treatment at 5.0 μM had the
greatest effect on the replicative capacity of WS cells
compared to untreated cells (illustrated for WS strainAG05229 where the replicative capacity increased from
20.5 PDs to 26.5 PDs: Figure 1d). The percentage in-
crease in experimental replicative capacity using MK2.III
at 5.0 μM for the two WS strains compared to untreated
cells of 50.3 ± 5.6% was statistically significant (Figure 1f;
Table 1). In contrast MK2 inhibition had little effect on
NDFs (21.9 PDs compared to 20.5 PDs at 5.0 μM for
NDF strain AG04552: Figure 1e). For the NDF strains,
MK2.III resulted in a statistically insignificant increase in
replicative capacity of 8.0 ± 7.0% (Figure 1f; Table 1). In
addition, the increase in replicative capacity by MK2.III
was significantly greater in WS fibroblasts compared to
NDFs (Table 1). MK2.III also increased replicative cap-
acity at 2.5 and 4.0 μM, but not to the degree seen using
5.0 μM, whereas 10 μM was inhibitory (Figure 1d-f). In
contrast SB203580 resulted in much greater increases in
replicative capacity for both NDFs and WS fibroblasts
(Figure 1d-f), in agreement with previous reports for these
cells [3,15]. The increase in replicative capacity using
SB203580 is significantly greater for WS fibroblasts than
for NDFs (Table 1), again consistent with previous data.
One of the defining features of WS fibroblasts is their
aged morphology and extensive F-actin stress fibre for-
mation even at low PD levels, and p38 inhibition using
SB203580 treatment reverted this morphology to that
seen in low PD NDFs ([3]; see Figure 1g). As F-actin
stress fibre formation is associated with HSP27 phos-
phorylation by MK2 [9], we examined this phenotype in
cells treated with MK2 inhibitors. For both WS strains,
many control cells were enlarged with extensive F-actin
stress fibres (Figure 1g). Continuous treatment with 5.0
μM MK2.III reverted this morphology, with the bulk of
treated cells being smaller and with few F-actin stress
fibres visible. With regard to this phenotype MK2.III
appeared to be more effective than SB203580, particu-
larly in WS strain AG03141F (Figure 1g). In contrast
very few enlarged cells with F-actin stress fibres were
seen in NDFs, and they were unaffected by treatment
with either SB203580 or MK2.III.
These data suggest that the accelerated senescence seen
in WS fibroblasts is due, at least partially, to activation of
MK2. However, MK2.III is less effective than the p38 in-
hibitor SB203580 at extending replicative capacity. There
are several possible reasons for this difference: firstly,
SB203580 may target more than one kinase involved in
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arrest via p38 may operate though multiple p38 target
proteins; thirdly, it may be that the therapeutic window
for MK2.III is too small, since it soon becomes inhibitory
to cellular growth above its optimal concentration. As our
previous work suggests that, of the known candidates for
SB203580, p38 is the primary target for its effects in WS
cells [13,17], and MK2.III is as effective as SB203580 at
reverting the cellular morphology phenotype, it is possible
that p38 inhibits cell growth via multiple targets. Possible
p38 effectors include the MNKs and MSKs that are acti-
vated in response to environmental stresses, the latter in a
manner inhibited by SB203580 [6] with the MSKs not
being inhibited by MK2.III [14]. In addition there are sev-
eral transcription factors that are p38 targets [6]. The
detailed p38 pathways and their effects on cellular prolif-
eration are not fully understood. It is important to note
that MK2.III does not have its effects by actually inhibiting
p38 [14]. However, because the possibility of a small thera-
peutic window for MK2.III remains, work is in progress to
synthesise or otherwise obtain other MK2 inhibitors with
different properties to extend this work. Overall, this work
provides support for the role of MK2 in accelerated cell
senescence in WS fibroblasts, and the possible therapeutic
targeting of MK2 in WS individuals, and thus supports fur-
ther work in this area when suitable MK2 inhibitors be-
come available.
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Methods: word file documenting materials and methods
used in this work.
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